New study aims to bring multiple myeloma treatment home, easing caregiver strain
NCT ID NCT06251076
First seen Jan 06, 2026 · Last updated Jun 08, 2026 · Updated 29 times
Summary
This study tests whether teclistamab, a drug for relapsed or refractory multiple myeloma, can be given safely in an outpatient setting instead of the hospital. It involves 15 patients who have tried at least three prior treatments. The goal is to develop clear procedures for outpatient care and measure how it affects caregivers' quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Conditions
Explore the condition pages connected to this study.